The ADC binds HER2 on tumor cells, is internalized, and releases a camptothecin payload that inhibits topoisomerase I, causing DNA damage and apoptosis. Topoisomerase I is the intracellular enzyme target of the payload, not the cell-surface antigen used for targeting.